ライフサイエンスコーパス: vulvar

1 nogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagn

2 e United States, as well as 32 prostatic, 30 vulvar, 24 ovarian, 20 cervical, and 30 testicular cance

3 was lower (58.3%) than cervical (73.6%) and vulvar (72.1%) detection (P = 0.05 and 0.07, respectivel

4 In vulvar and cervical carcinomas, sentinel node identifica

5 Vulvar and cervical HPV16 prevalence within the control

6 this intention-to-treat analysis, VE against vulvar and cervical HPV16/18 were comparable 4 years fol

7 ping on voided-urine and clinician-collected vulvar and cervical samples from 72 women undergoing col

8 sit of the Costa Rica Vaccine Trial provided vulvar and cervical samples.

9 Subrenal xenografts of ROPV-infected rabbit vulvar and penile sheath tissues were strongly positive

10 vical cancer, and now also for prevention of vulvar and vaginal cancers, confirmed 98-100% vaccine ef

11 ation, the incidence of high-grade cervical, vulvar and vaginal disease related to HPV 31, 33, 45, 52

12 Symptoms and signs can include intense vulvar and vaginal itching, low back pain, uterine cramp

13 enotype detectable in 25% of urine, 33.8% of vulvar, and 31.9% of cervical samples overall, with prev

14 hampion HPV vaccination to prevent cervical, vulvar, and vaginal cancers, even though these benefits

15 cytologic and HPV testing) and any cervical, vulvar, and vaginal histopathological findings for all w

16 We compared cervical and vulvar areas of the vagina in young nullipara and older

17 In women with symptoms of vaginal and/or vulvar atrophy, lubricants in addition to vaginal moistu

18 We obtained a vulvar biopsy of autologous tissue from every patient.

19 h node (LN) status in patients with invasive vulvar cancer (VC) scheduled for inguinofemoral LN disse

20 f western Washington who were diagnosed with vulvar cancer between April 1991 and June 1994.

21 from two different groups: 265 subjects in a vulvar cancer case-control study and 107 healthy volunte

22 (vulvar intraepithelial neoplasia grade 2/3, vulvar cancer), and vaginal disease (vaginal intraepithe

23 sia grade 3, 4.97 (95% CI, 3.26 to 7.57) for vulvar cancer, 13.66 (93% CI, 9.69 to 19.25) for vulvar

24 highest solid tumor O/E ratios were 4317 for vulvar cancer, 2362 for esophageal cancer, and 706 for h

25 uch as endometrial cancer, uterine sarcomas, vulvar cancer, and vaginal carcinoma but with less well

26 ed in studies of cervical adenocarcinoma and vulvar cancer.

27 1 null genotype are not at increased risk of vulvar cancer.

28 e GSTM1 null genotype are at altered risk of vulvar cancer.

29 breast, 5; pancreas, 5; ovarian/endometrial/vulvar cancers, 3; and de novo cholangiocarcinoma, 4).

30 e to patients with cervical, endometrial, or vulvar cancers.

31 port the concept of at least two pathways in vulvar carcinogenesis.

32 arcinoma (approximately 100%) and similar to vulvar carcinoma (approximately 50%).

33 g malignancies: 9 myelodysplasia/leukemia, 1 vulvar carcinoma and metastatic melanoma, 1 cervical car

34 symptom control, scarring, and occurrence of vulvar carcinoma between compliant and partially complia

35 amous epithelial alterations associated with vulvar carcinoma, including hyperplasia and lichen scler

36 complicated by loss of vulvar structure and vulvar carcinoma.

37 at increased risk of development of invasive vulvar carcinoma.

38 of loss of heterozygosity (LOH) within four vulvar carcinomas and in adjacent vulvar epithelia.

39 (aneuploidy) occurs in the skin surrounding vulvar carcinomas.

40 The vulvar cell lines were the most sensitive, and the ovari

41 much more potent growth inhibitor of the two vulvar cell lines, which is consistent with strong RARga

42 Women collected daily genital swabs of the vulvar, cervicovaginal, and perianal areas for HSV cultu

43 s (HPV) infections, and chronic inflammatory vulvar dermatoses.

44 skin biopsies failed to reveal an underlying vulvar dermatosis or autoimmune bullous disorder.

45 inoma in situ, invasive cervical carcinoma), vulvar disease (vulvar intraepithelial neoplasia grade 2

46 fects a spectrum of women with granulomatous vulvar diseases, human papillomavirus (HPV) infections,

47 owed that chronic vulval pain (vulvodynia or vulvar dysaesthesia) is associated with worse depressive

48 in one CKI-responsive cell line (A431 human vulvar epidermoid carcinoma cells with functional Rb) an

49 ithin four vulvar carcinomas and in adjacent vulvar epithelia.

50 hat many genetic alterations in the adjacent vulvar epithelium are not directly related to the invasi

51 rrounding vulvar skin were obtained from all vulvar excisions performed for squamous neoplasia at Alb

52 the agreement of urine HPV with cervical and vulvar HPV was moderate (kappa = 0.55) and substantial (

53 Independent risk factors for vulvar HPV were similar to cervix and included: age (adj

54 VE against 1-time detection of vulvar HPV16/18 among HPV vaccinated versus unvaccinated

55 Vulvar HPV16/18 VE (54.1%; 95% confidence interval [CI],

56 Vaccine efficacy (VE) against vulvar human papillomavirus (HPV) infection has not been

57 ntraepithelial neoplasia and, in some cases, vulvar hyperplasia, and lichen sclerosis.

58 gated in paraffin-embedded VSCC and adjacent vulvar intraepithelial neoplasia (VIN) and VLS specimens

59 ites of normal squamous mucosa, hyperplasia, vulvar intraepithelial neoplasia (VIN), and carcinoma we

60 Samples of SCC, vulvar intraepithelial neoplasia (VIN), and surrounding

61 l assay supports a monoclonal derivation for vulvar intraepithelial neoplasia and, in some cases, vul

62 nvasive cervical carcinoma), vulvar disease (vulvar intraepithelial neoplasia grade 2/3, vulvar cance

63 ar cancer, 13.66 (93% CI, 9.69 to 19.25) for vulvar intraepithelial neoplasia grade 3, 86.08 (95% CI,

64 Biopsy-proved squamous cell carcinoma or vulvar intraepithelial neoplasia occurred during follow-

65 Provided cancer is not suspected, usual-type vulvar intraepithelial neoplasia treatment, including me

66 lasms of the female genital tract, including vulvar intraepithelial neoplasia, presumably are derived

67 ective and tolerable for treating usual-type vulvar intraepithelial neoplasia?

68 Of 8 vulvar intraepithelial neoplasias analyzed, 7 were score

69 Vulvar lesions failed to heal in association with trials

70 Adult vulvar lichen sclerosis (VLS) may be complicated by loss

71 f vulvar squamous cell carcinoma (VSCC) from vulvar lichen sclerosus (VLS) is unknown.

72 roids are the current first-line therapy for vulvar lichen sclerosus (VLS).

73 Physicians managing patients with vulvar LS should be aware of the possibility of vaginal

74 Two cases of severe vulvar LS with vaginal involvement are reported.

75 alignancies, Kaposi's sarcomas, and cervical/vulvar neoplasms are the most common, but visceral malig

76 The rate of high-grade cervical, vulvar, or vaginal disease irrespective of HPV type (i.e

77 The rate of high-grade cervical, vulvar, or vaginal disease related to HPV-31, 33, 45, 52

78 of two cell lines each derived from cervix, vulvar, ovarian, and head/neck tumors with similar effic

79 and vulvodynia, a debilitating, unexplained vulvar pain condition.

80 dentified 125 women experiencing symptoms of vulvar pain consistent with vulvodynia and 125 age- and

81 tment for socioeconomic position, women with vulvar pain versus controls were 2.6 times more likely t

82 subsequent malignancies (cervical, vaginal, vulvar, penile, anal, tongue, tonsillar, and oropharynge

83 Swabs of labial, vulvar, perineal, perianal, endocervical, and ectocervic

84 from the Chauvet paintings reveal that the "vulvar" representations from southwestern France are as

85 nding sensitivity and specificity values for vulvar sampling were 92% (95% CI = 74 to 99) and 40.5% (

86 in 32 of 48 cervical SCCs (67%) and 10 of 23 vulvar SCCs (43%).

87 sue from cases of cervical SCCs (n = 48) and vulvar SCCs (n = 23) were retrieved from the archives of

88 PD-L1 expression in a subset of cervical and vulvar SCCs and identifies a class of patients that are

89 ty occurring in synchronous skin surrounding vulvar SCCs, we investigated abnormalities in chromosome

90 iopsy specimens from 48 cervical SCCs and 23 vulvar SCCs.

91 ts, epithelial fibers were mainly present in vulvar segments and most nerve fibers were found in the

92 nal (SIR for men, 21.5; SIR for women, 7.8), vulvar (SIR, 14.8), vaginal (SIR, 5.9), cervical (SIR, 1

93 with SCC (1.8 +/- 0.4) compared with control vulvar skin (1.5 +/- 0.05).

94 an four FISH signals), whereas 56% of normal vulvar skin associated with cancer did.

95 al acute genital ulceration (NAGU) is a rare vulvar skin condition typically affecting girls and youn

96 Normal vulvar skin controls did not exhibit chromosome 17 polys

97 Controls of normal vulvar skin not associated with cancer were used for com

98 2 nonneoplastic, and 9 histologically normal vulvar skin samples.

99 aepithelial neoplasia (VIN), and surrounding vulvar skin were obtained from all vulvar excisions perf

100 Vulvar squamous cell carcinoma (SCC) affects a spectrum

101 ular mechanism leading to the development of vulvar squamous cell carcinoma (VSCC) from vulvar lichen

102 clerosis (VLS) may be complicated by loss of vulvar structure and vulvar carcinoma.

103 continue to reduce morbidity associated with vulvar surgery and groin node dissection.

104 a 15-month history of persistent, nonhealing vulvar ulcerations due to herpes simplex virus (HSV) typ

105 %; NPV range, 79%-80%; herpes simplex virus, vulvar ulcerations: sensitivity, 20%; specificity, 98%;

106 lthough the etiology of NAGU is unknown, the vulvar ulcers may result from an exuberant immune respon

107 l types of human cancer, including cervical, vulvar, vaginal, penile, anal, and head-and-neck cancers

108 Vulvar/vaginal human papillomavirus (HPV) infections may

109 applying liquid lidocaine compresses to the vulvar vestibule before penetration.

110 RH, 3.54; 95% CI, 1.37-9.10), and history of vulvar warts (RH, 2.73; 95% CI, 1.27-5.87).